Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis

Iranian Journal of Microbiology

Volumn 5, Issue 1, 2013, Pages 86-90

  Mahmoudabadi, Ali Zarei ^a   Najafyan, Mahin ^a   Moghimipour, Eskandar ^a   Alwanian, Maryam ^a   Seifi, Zahra ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Candida albicans; Clotrimazole; Terbinafine; Vulvovaginal candidiasis

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE; TERBINAFINE;

ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VAGINA CANDIDIASIS;

EID: 84873417825     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol 2006; 108: 1432-1437.
2. Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Australian New Zealand J Obstet Gynaecol 2007; 47: 262-272.
3. Meyer H, Goettlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006; 49: 202-209.
4. Novikova N, Rodrigues A, Mårdh PA. Can the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar? Infect Dis Obstet Gynecol 2002; 10: 89-92.
5. Nyirjesy P, Peyton C, Velma Weitz M, Mathew L, Culhane JF. Causes of Chronic vaginitis, analysis of a prospective database of affected women. Obstet Gynecol 2006; 108: 1185-1191.
6. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007; 126: 216-219.
7. Zarei Mahmoudabadi A, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci 2010; 26: 607-610.
8. Aghamirian MR, Keshavarz D, Jahani Hashemi H, Sadeghi Qazvini M. Agents associated with Candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Uni Med 2007; 11: 35-39.
9. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162.
10. Ventolini G, Baggish MS, Walsh PM. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med 2006; 51: 475-478.
11. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006; 49: 471-475.
12. García Heredia M, García SD, Copolillo EF, Cora Eliseth M, Barata AD, Vay CA, et al. Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents. Rev Argent Microbiol 2006; 38: 9-12.
13. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol 2011; 3: 183-188.
14. Shivakumar V, Okade R, Rajkumar V, Sajitha K, Prasad SR. Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J Dermatol 2011; 56: 121-122.
15. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol 2012 May 28. doi: 10.1111/j.1468-3083.2012.04584.x. (Epub ahead of print)
16. López-Martínez R. Candidosis, a new challenge. Clin Dermatol 2010; 28: 178-184.
17. Gianni C. Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol 2010; 145: 415-424.
18. Szigeti G, Sedaghati E, Zarei Mahmoudabadi A, Naseri A, Kocsubé S, Vágvölgyi C, Varga J. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran. Mycoses 2012; 55: 333-338.
19. Jamilian M, Mashadi E, Sarmadi F, Ghaznavi A, Bani Jamali M, Farhadi E, et al. Frequency of vulvovaginal candidiasis species in non-pregnant 15-50 years old women in spring 2005 in Arak. J Arak Uni Med Sci 2007; 2: 7-14.
20. Us E, Cengiz SA. Prevalence and phenotypic evaluation of Candida dubliniensis in pregnant women with vulvovaginal candidosis in a university hospital in Ankara. Mycoses 2006; 50: 13-20.
21. Aali BS, Tohidi A. Prevalence of Candida vaginitis among symptomatic patients in Kerman. J Qazvin Uni Med Sci 2000; 13: 48-42.
22. Khorsandi M, Modares Gilani M, Khosravi AR. Recovery and recurrence of vaginal candidiasis after oral and intravaginal treatment. J Qazvin Uni Med Sci 2000; 14: 25-29.
23. Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 7: 403-408.
24. Ferahbas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther 2006; 13: 332-336.